Eyenovia

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2014-01-01

Employees: 57

Market Cap: $43.8M

Website: http://www.eyenovia.com

Introduction: Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Clinical Trials

Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation

Phase 4

Completed

Conditions: Mydriasis

Interventions: Combination Product: MydCombi

First Posted Date: 2024-01-22

Last Posted Date: 2024-04-18

Lead Sponsor: Eyenovia Inc.

Target Recruit Count: 30

Registration Number: NCT06217796

Locations: 🇺🇸
SUNY, New York, New York, United States

Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults

Phase 3

Completed

Conditions: Presbyopia

Interventions: Combination Product: Pilocarpine Ophthalmic administered with the Optejet dispenser
Combination Product: Placebo administered with the Optejet dispenser

First Posted Date: 2021-11-10

Last Posted Date: 2023-09-11

Lead Sponsor: Eyenovia Inc.

Target Recruit Count: 145

Registration Number: NCT05114486

Locations: 🇺🇸
VISION-2 Study Site #61, Draper, Utah, United States
🇺🇸
VISION-2 Study Site #56, Louisville, Kentucky, United States
🇺🇸
VISION-2 Study Site #19, Columbus, Ohio, United States

and more 6 locations

Evaluation of Pupil Dilation Speed With the MAP Dispenser

Phase 4

Completed

Conditions: Mydriasis

Interventions: Drug: tropicamide-phenylephrine fixed combination ophthalmic solution

First Posted Date: 2021-05-28

Last Posted Date: 2025-01-09

Lead Sponsor: Eyenovia Inc.

Target Recruit Count: 61

Registration Number: NCT04907474

Locations: 🇲🇽
CODET Vision Institute, Tijuana, Baja California, Mexico

Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults

Phase 3

Completed

Conditions: Presbyopia

Interventions: Drug: Pilocarpine Ophthalmic
Drug: Placebo

First Posted Date: 2020-12-08

Last Posted Date: 2021-08-09

Lead Sponsor: Eyenovia Inc.

Target Recruit Count: 84

Registration Number: NCT04657172

Locations: 🇺🇸
VISION-1 Study Site #54, Fort Collins, Colorado, United States
🇺🇸
VISION-1 Study Site #21, Azusa, California, United States
🇺🇸
VISION-1 Study Site #53, Orlando, Florida, United States

and more 6 locations

Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

Phase 3

Terminated

Conditions: Myopia

Interventions: Drug: Atropine 0.1% Ophthalmic Solution
Drug: Atropine 0.01% Ophthalmic Solution
Drug: Placebo Ophthalmic Solution

First Posted Date: 2019-05-08

Last Posted Date: 2025-01-06

Lead Sponsor: Eyenovia Inc.

Target Recruit Count: 438

Registration Number: NCT03942419

Locations: 🇺🇸
University of Alabama at Birmingham School of Optometry, Birmingham, Alabama, United States
🇺🇸
Midwestern University, Downers Grove, Illinois, United States
🇺🇸
Canyon City Eyecare, Azusa, California, United States

and more 14 locations